<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03374826</url>
  </required_header>
  <id_info>
    <org_study_id>NL62441.068.17</org_study_id>
    <nct_id>NCT03374826</nct_id>
  </id_info>
  <brief_title>PET-MRI for Axillary Staging in Node Negative Breast Cancer Patients</brief_title>
  <official_title>Non-invasive Axillary Lymph Node Staging in Breast Cancer With PET-MRI</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maastricht University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Maastricht University Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Axillary lymph node status is an important prognostic factor for patients with breast cancer.&#xD;
      After breast cancer diagnosis, current nodal staging consists of axillary ultrasound (US)&#xD;
      combined with tissue sampling when deemed necessary. In case of positive axillary lymph&#xD;
      nodes, patients will undergo axillary lymph node dissection (ALND). In case of no suspicious&#xD;
      axillary lymph nodes (i.e. clinically node negative patients), patients will undergo sentinel&#xD;
      lymph node biopsy (SLNB). This surgical nodal staging is accompanied by co-morbidity. In&#xD;
      theory, if non-invasive imaging can evaluate the lymph node status accurately, a node&#xD;
      negative patient would no longer have to undergo axillary surgery. Since MRI is suitable for&#xD;
      soft tissue imaging and PET has the advantage of showing increased metabolic uptake in lymph&#xD;
      node metastases, a combination of these techniques in hybrid PET/MRI would be highly&#xD;
      desirable. If dedicated axillary hybrid PET/MRI is equally accurate to SLNB for the detection&#xD;
      of negative axillary lymph nodes, work-up could be more efficient by bypassing SLNB. However,&#xD;
      the accuracy of dedicated axillary hybrid PET/MRI needs to be compared with the pathological&#xD;
      outcome of SLNB (gold standard) first.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 22, 2018</start_date>
  <completion_date type="Anticipated">August 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Accuracy of dedicated hybrid PET/MRI</measure>
    <time_frame>Participants will be followed from the moment of first outpatient clinic visit until final breast surgery, an expected average of 4 weeks</time_frame>
    <description>Accuracy (sensitivity, negative predictive value (NPV) and false negative rate (FNR)) of dedicated axillary hybrid PET/MRI to exclude axillary lymph node metastases will be calculated.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Accuracy of T2w MRI, DWI and Hybrid PET/MRI</measure>
    <time_frame>Participants will be followed from the moment of first outpatient clinic visit until final breast surgery, an expected average of 4 weeks</time_frame>
    <description>Accuracy (sensitivity, negative predictive value (NPV) and false negative rate (FNR)) of three MRI sequences (T2w, DWI and hybrid PET/MRI) to exclude axillary lymph node metastases will be calculated separately as well.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">125</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Breast Neoplasms</condition>
  <condition>Breast Diseases</condition>
  <arm_group>
    <arm_group_label>Dedicated axillary hybrid PET-MRI axilla</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Dedicated axillary hybrid PET-MRI</intervention_name>
    <description>All clinically node negative patients will undergo a hybrid PET-MRI axilla preoperatively, followed by breast surgery and SLNB.</description>
    <arm_group_label>Dedicated axillary hybrid PET-MRI axilla</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Female patient with histologically confirmed breast cancer and clinically confirmed&#xD;
             negative lymph nodes in the axilla, scheduled to undergo SLNB&#xD;
&#xD;
          2. Patients who are willing and able to undergo the study procedures&#xD;
&#xD;
          3. The patient has provided personally written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients treated with neoadjuvant systemic therapy prior to axillary nodal staging&#xD;
&#xD;
          2. Patients with clinically positive axillary lymph nodes&#xD;
&#xD;
          3. Age &lt; 18 years&#xD;
&#xD;
          4. Inability to provide informed consent&#xD;
&#xD;
          5. Pregnancy&#xD;
&#xD;
          6. Weight &gt;100 kg (because of the format of the PET/MRI scanner)&#xD;
&#xD;
          7. General contraindications for MRI (such as pacemaker, aneurysm clips, metallic device&#xD;
             in their body, severe claustrophobia) or PET (i.e. known allergy to 18F-FDG)&#xD;
&#xD;
          8. Hyperglycaemia (&gt; 11 mmol/L) at the time of 18F-FDG injection&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Maastricht University Medical Center</name>
      <address>
        <city>Maastricht</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kees de Mooij, MD</last_name>
      <phone>+31 43 388 1575</phone>
      <email>c.demooij@maastrichtuniversity.nl</email>
    </contact>
    <investigator>
      <last_name>Marjolein Smidt, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>November 28, 2017</study_first_submitted>
  <study_first_submitted_qc>December 11, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 15, 2017</study_first_posted>
  <last_update_submitted>September 8, 2020</last_update_submitted>
  <last_update_submitted_qc>September 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Breast Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

